Ross Osborn
Stock Analyst at Cantor Fitzgerald
(2.14)
# 2,908
Out of 5,124 analysts
119
Total ratings
36.36%
Success rate
-1.56%
Average return
Main Sectors:
Stocks Rated by Ross Osborn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CVRX CVRx, Inc. | Maintains: Overweight | $11 → $13 | $7.10 | +83.10% | 4 | Nov 6, 2025 | |
| PRE Prenetics Global | Maintains: Overweight | $26 → $32 | $15.78 | +102.79% | 8 | Oct 29, 2025 | |
| ORGO Organogenesis Holdings | Maintains: Overweight | $7 → $9 | $4.64 | +94.17% | 4 | Aug 8, 2025 | |
| LMAT LeMaitre Vascular | Maintains: Neutral | $92 → $95 | $80.05 | +18.68% | 2 | Aug 6, 2025 | |
| SIBN SI-BONE | Reiterates: Overweight | $25 | $19.79 | +26.33% | 10 | Aug 5, 2025 | |
| MDXG MiMedx Group | Maintains: Overweight | $11 → $12 | $6.48 | +85.19% | 5 | Jul 31, 2025 | |
| BVS Bioventus | Initiates: Overweight | $12 | $7.21 | +66.44% | 1 | Jul 7, 2025 | |
| XGN Exagen | Maintains: Overweight | $8 → $7 | $6.04 | +15.89% | 6 | May 15, 2025 | |
| LUCD Lucid Diagnostics | Reiterates: Overweight | $2 | $1.12 | +78.57% | 6 | May 15, 2025 | |
| NPCE NeuroPace | Reiterates: Overweight | $17 | $15.17 | +12.06% | 7 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $9 | $2.83 | +218.02% | 11 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $46 | $22.99 | +100.09% | 6 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $8 | $0.64 | +1,143.78% | 10 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $24 | $31.00 | -22.58% | 3 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $4 | $1.97 | +103.05% | 4 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $4.92 | +82.93% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $21 | $3.47 | +505.19% | 10 | Dec 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 | $4.50 | +255.56% | 4 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3.5 | $1.84 | +90.22% | 5 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $2.5 | $0.27 | +815.75% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $1.16 | - | 7 | Apr 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $258 | $7.33 | +3,423.87% | 2 | Aug 18, 2023 |
CVRx, Inc.
Nov 6, 2025
Maintains: Overweight
Price Target: $11 → $13
Current: $7.10
Upside: +83.10%
Prenetics Global
Oct 29, 2025
Maintains: Overweight
Price Target: $26 → $32
Current: $15.78
Upside: +102.79%
Organogenesis Holdings
Aug 8, 2025
Maintains: Overweight
Price Target: $7 → $9
Current: $4.64
Upside: +94.17%
LeMaitre Vascular
Aug 6, 2025
Maintains: Neutral
Price Target: $92 → $95
Current: $80.05
Upside: +18.68%
SI-BONE
Aug 5, 2025
Reiterates: Overweight
Price Target: $25
Current: $19.79
Upside: +26.33%
MiMedx Group
Jul 31, 2025
Maintains: Overweight
Price Target: $11 → $12
Current: $6.48
Upside: +85.19%
Bioventus
Jul 7, 2025
Initiates: Overweight
Price Target: $12
Current: $7.21
Upside: +66.44%
Exagen
May 15, 2025
Maintains: Overweight
Price Target: $8 → $7
Current: $6.04
Upside: +15.89%
Lucid Diagnostics
May 15, 2025
Reiterates: Overweight
Price Target: $2
Current: $1.12
Upside: +78.57%
NeuroPace
May 14, 2025
Reiterates: Overweight
Price Target: $17
Current: $15.17
Upside: +12.06%
Apr 1, 2025
Maintains: Overweight
Price Target: $12 → $9
Current: $2.83
Upside: +218.02%
Mar 26, 2025
Reiterates: Overweight
Price Target: $46
Current: $22.99
Upside: +100.09%
Mar 7, 2025
Reiterates: Overweight
Price Target: $8
Current: $0.64
Upside: +1,143.78%
Mar 5, 2025
Reiterates: Overweight
Price Target: $24
Current: $31.00
Upside: -22.58%
Feb 21, 2025
Reiterates: Overweight
Price Target: $4
Current: $1.97
Upside: +103.05%
Jan 7, 2025
Initiates: Overweight
Price Target: $9
Current: $4.92
Upside: +82.93%
Dec 24, 2024
Reiterates: Overweight
Price Target: $21
Current: $3.47
Upside: +505.19%
Nov 5, 2024
Reiterates: Overweight
Price Target: $16
Current: $4.50
Upside: +255.56%
Aug 8, 2024
Reiterates: Overweight
Price Target: $3.5
Current: $1.84
Upside: +90.22%
May 16, 2024
Reiterates: Overweight
Price Target: $2.5
Current: $0.27
Upside: +815.75%
Apr 12, 2024
Reiterates: Neutral
Price Target: n/a
Current: $1.16
Upside: -
Aug 18, 2023
Reiterates: Neutral
Price Target: $258
Current: $7.33
Upside: +3,423.87%